Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GLOW Participants | New patients, those who are newly prescribed a GLP-1RA medication will be invited to participate in the study where different measurements will be completed to assess body composition, hormone levels, muscle strength and nutrition. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Body weight | Assess changes in body weight by measuring weight on a calibrated scale | Baseline through 6-month visit |
| Body composition | Assess changes in lean and fat mass and fat-free mass in kilograms by total body DXA scan | Baseline through 6-month visit |
| Bone mineral density (BMD) | Assess changes in bone mineral density (BMD) by completing femur DXA scans | Baseline through 6-month visit |
| Muscle function | Assess muscle function changes in pounds by completing Grip strength tests | Baseline through 6-month visit |
| Muscle function | Assess changes to muscle function by the number of repetitions achieved per 30-second Sit-to-stand test | Baseline through 6-month visit |
| Measure | Description | Time Frame |
|---|---|---|
| Estrogen level role in BMD changes during GLP-1RA therapy | Examine the moderating role of estrogen levels on changes in bone mineral density (BMD) during GLP-1RA therapy. | Baseline through 6-month visit |
| Estrogen level role in muscle function changes during GLP-1RA therapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Women in midlife who are establishing care at the KU OBGYN's weight management clinic
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Johanna Finkle, MD | Contact | (913) 588-5478 | jfinkle2@kumc.edu | |
| Holly Hull, PhD | Contact | 913-945-5838 | hhull@kumc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Johanna Finkle, MD | University of Kansas Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Kansas Medical Center | Recruiting | Kansas City | Kansas | 66160 | United States |
Not provided
Not provided
Not provided
Not provided
Examine the moderating role of estrogen levels on changes in muscle function during GLP-1RA therapy. |
| Baseline through 6-month visit |
| Diet intake | Examine changes in dietary intake including protein consumption by collecting 24-hrs diet recalls. | Baseline through 6-month visit |
| Diet quality | Examine changes in dietary quality by collecting 24-hrs diet recalls. | Baseline through 6-month visit |